357 related articles for article (PubMed ID: 33174454)
1. Long-term
Lowjaga KAAT; Kirstgen M; Müller SF; Goldmann N; Lehmann F; Glebe D; Geyer J
Am J Physiol Gastrointest Liver Physiol; 2021 Jan; 320(1):G66-G80. PubMed ID: 33174454
[TBL] [Abstract][Full Text] [Related]
2. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.
Yan H; Peng B; Liu Y; Xu G; He W; Ren B; Jing Z; Sui J; Li W
J Virol; 2014 Mar; 88(6):3273-84. PubMed ID: 24390325
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes.
König A; Döring B; Mohr C; Geipel A; Geyer J; Glebe D
J Hepatol; 2014 Oct; 61(4):867-75. PubMed ID: 24845614
[TBL] [Abstract][Full Text] [Related]
4. Selective hepatitis B and D virus entry inhibitors from the group of pentacyclic lupane-type betulin-derived triterpenoids.
Kirstgen M; Lowjaga KAAT; Müller SF; Goldmann N; Lehmann F; Alakurtti S; Yli-Kauhaluoma J; Glebe D; Geyer J
Sci Rep; 2020 Dec; 10(1):21772. PubMed ID: 33303817
[TBL] [Abstract][Full Text] [Related]
5. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
Donkers JM; Zehnder B; van Westen GJP; Kwakkenbos MJ; IJzerman AP; Oude Elferink RPJ; Beuers U; Urban S; van de Graaf SFJ
Sci Rep; 2017 Nov; 7(1):15307. PubMed ID: 29127322
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
Ni Y; Lempp FA; Mehrle S; Nkongolo S; Kaufman C; Fälth M; Stindt J; Königer C; Nassal M; Kubitz R; Sültmann H; Urban S
Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467
[TBL] [Abstract][Full Text] [Related]
7. Interactions of Na
Zakrzewicz D; Geyer J
Biol Chem; 2023 Jun; 404(7):673-690. PubMed ID: 37103224
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors.
Kirstgen M; Lowjaga KAAT; Müller SF; Goldmann N; Lehmann F; Glebe D; Baringhaus KH; Geyer J
Viruses; 2021 Apr; 13(4):. PubMed ID: 33921515
[TBL] [Abstract][Full Text] [Related]
9. IFITM3 Interacts with the HBV/HDV Receptor NTCP and Modulates Virus Entry and Infection.
Palatini M; Müller SF; Kirstgen M; Leiting S; Lehmann F; Soppa L; Goldmann N; Müller C; Lowjaga KAAT; Alber J; Ciarimboli G; Ziebuhr J; Glebe D; Geyer J
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458456
[TBL] [Abstract][Full Text] [Related]
10. Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP).
Veloso Alves Pereira I; Buchmann B; Sandmann L; Sprinzl K; Schlaphoff V; Döhner K; Vondran F; Sarrazin C; Manns MP; Pinto Marques Souza de Oliveira C; Sodeik B; Ciesek S; von Hahn T
PLoS One; 2015; 10(2):e0117152. PubMed ID: 25646622
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine 146 of the Human Na
Zakrzewicz D; Leidolf R; Kunz S; Müller SF; Neubauer A; Leiting S; Goldmann N; Lehmann F; Glebe D; Geyer J
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746730
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
Nkongolo S; Ni Y; Lempp FA; Kaufman C; Lindner T; Esser-Nobis K; Lohmann V; Mier W; Mehrle S; Urban S
J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.
Shimura S; Watashi K; Fukano K; Peel M; Sluder A; Kawai F; Iwamoto M; Tsukuda S; Takeuchi JS; Miyake T; Sugiyama M; Ogasawara Y; Park SY; Tanaka Y; Kusuhara H; Mizokami M; Sureau C; Wakita T
J Hepatol; 2017 Apr; 66(4):685-692. PubMed ID: 27890789
[TBL] [Abstract][Full Text] [Related]
14. Molecular regulation of the hepatic bile acid uptake transporter and HBV entry receptor NTCP.
Appelman MD; Wettengel JM; Protzer U; Oude Elferink RPJ; van de Graaf SFJ
Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Aug; 1866(8):158960. PubMed ID: 33932583
[TBL] [Abstract][Full Text] [Related]
15. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus.
Yan H; Li W
Dig Dis; 2015; 33(3):388-96. PubMed ID: 26045274
[TBL] [Abstract][Full Text] [Related]
16. Identification of Novel HBV/HDV Entry Inhibitors by Pharmacophore- and QSAR-Guided Virtual Screening.
Kirstgen M; Müller SF; Lowjaga KAAT; Goldmann N; Lehmann F; Alakurtti S; Yli-Kauhaluoma J; Baringhaus KH; Krieg R; Glebe D; Geyer J
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452354
[TBL] [Abstract][Full Text] [Related]
17. Development of a mass spectrometric screening assay for hepatitis B virus entry inhibitors.
Goh B; Choi J; Kang JA; Park SG; Seo J; Kim TY
J Pharm Biomed Anal; 2020 Jan; 178():112959. PubMed ID: 31722821
[TBL] [Abstract][Full Text] [Related]
18. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T
J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
[TBL] [Abstract][Full Text] [Related]
19. Establishment of a Monoclonal Antibody against Human NTCP That Blocks Hepatitis B Virus Infection.
Takemori T; Sugimoto-Ishige A; Nishitsuji H; Futamura Y; Harada M; Kimura-Someya T; Matsumoto T; Honma T; Tanaka M; Yaguchi M; Isono K; Koseki H; Osada H; Miki D; Saito T; Tanaka T; Fukami T; Goto T; Shirouzu M; Shimotohno K; Chayama K
J Virol; 2022 Mar; 96(5):e0168621. PubMed ID: 34985994
[TBL] [Abstract][Full Text] [Related]
20. NTCP Oligomerization Occurs Downstream of the NTCP-EGFR Interaction during Hepatitis B Virus Internalization.
Fukano K; Oshima M; Tsukuda S; Aizaki H; Ohki M; Park SY; Wakita T; Wakae K; Watashi K; Muramatsu M
J Virol; 2021 Nov; 95(24):e0093821. PubMed ID: 34613794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]